Citations

Bacterial Toxin Research Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

4918 total record number 290 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 21 out of 492
4918 citations found

Resting-state functional magnetic resonance imaging reveals functional connectivity alteration in the experimental autoimmune encephalomyelitis model of multiple sclerosis

Bontempi, P;Piccolantonio, G;Busato, A;Conti, A;Angelini, G;Lopez, N;Bani, A;Constantin, G;Marzola, P;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Immunogenicity and efficacy studies of Endo H in vivo deglycosylated Protective Antigen from Bacillus anthracis as a vaccine candidate against anthrax

Mamedov, T;Gun, N;Gulec, B;Khozeini, H;Ungor, R;Yuksel, D;Arslan, A;Dilik, Z;Deniz, D;Goven, N;Mammadova, G;Hasanova, G;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Immunogenicity Studies of PA83 variants in Mice

    Immunogenicity studies were performed with 3 and 10 μg of plant-produced dPA83(E), dPA83(P) and commercial recombinant PA (rPA, List Biological Laboratories, Campbell, CA, used as a positive control) proteins, administered intraperitoneally in seven- to eight-week-old Balb/c mice (6 animals/group). Mice were injected with three doses of protein samples adsorbed in 0.3% Alhydrogel at three-week intervals (day 0, 21 and 42). …

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis

Multimodal sensory control of motor performance by glycinergic interneurons of the mouse spinal cord deep dorsal horn

Gradwell, MA;Ozeri-Engelhard, N;Eisdorfer, JT;Laflamme, OD;Gonzalez, M;Upadhyay, A;Medlock, L;Shrier, T;Patel, KR;Aoki, A;Gandhi, M;Abbas-Zadeh, G;Oputa, O;Thackray, JK;Ricci, M;George, A;Yusuf, N;Keating, J;Imtiaz, Z;Alomary, SA;Bohic, M;Haas, M;Hernandez, Y;Prescott, SA;Akay, T;Abraira, VE;

Product: Anti-Cholera Toxin B Subunit (Goat)

Methods employed in a 2021 population-based serosurvey in Somalia

Hossain, M;Ali, A;Clary, C;Cooley, G;Farid, M;Gerber, S;Hoff, N;Ibrahim, A;Mainou, B;Malik, D;Martin, H;Mdodo, R;Mengistu, K;Obsie, A;Reynolds, Z;Rhoda, D;Shube, M;Sinai, C;Trimner, M;Webeck, J;

Product: Diphtheria Toxoid, from Corynebacterium diphtheriae

Minimizing Shear Stress in Cell Signaling Studies

Mendez, J;Toker, A;

Product: Cholera Toxin (AZIDE-FREE) from Vibrio cholerae

The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers

Jodl, SJ;Ten Voorde, W;Klein, S;Wagenfeld, A;Zollmann, FS;Feldmüller, M;Klarenbeek, NB;de Bruin, DT;Jansen, MAA;Rissmann, R;Rohde, B;Moerland, M;

Product: LIST™ HPT™ from Escherichia coli O113

  • Systemic LPS challenge

    After participants had undergone the IMQ skin challenge, an i.v. LPS challenge was performed on Day 7 after the start of treatment. All participants received 1 ng/kg purified Escherichia coli O113 LPS (List Labs, US, Lot #94332B4) reconstituted in 0.5 mL glucose 2.5%–sodium chloride (NaCl) 0.45% and administered as a 2- min infusion. To ensure that participants stayed adequately hydrated, glucose 2.5%–NaCl 0.45% was infused, starting 2 h prior to LPS administration and continuing until 6 h afterwards.18 Circulating inflammatory proteins (acute phase proteins, cytokines), leukocyte differentiation, and clinical parameters (pulse rate, blood pressure, and temperature) were evaluated over time, starting 0.5 h after the end of the infusion and ending up to 24 h after infusion.

    Product #9433 – GMP LPS Lipopolysaccharide List™ Hpt™ From Escherichia Coli Type O113

Species-specific NLRP3 regulation and its role in CNS autoinflammatory diseases

Koller, B;Nguyen, M;Snouwaert, J;Gabel, C;Ting, J;

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Anthrax lethal toxin List Biological Laboratories Inc. #171B/#172B

    Treatments

    See Table S1 for list of Figures/panels in each figure and corresponding dose and exposure time. General information for the methods is provided here. To induce cytokine release from macrophages, microglia and BMDM cells were primed for 4–5 h (or time indicated in Table S1)with 1 μg/mL of LPS in culture medium, and some cells were pre-treated with 1 μM of CP456773/MCC950 for 30 min before ATP stimulation. Cells were then pulsed with 5 mM ATP for 30 min. For cytokine induction by anthrax lethal toxin (LeTx), LPS-primed cells were treated with LeTx at a final concentration of 250 ng/mL (LF and PA) for 3 h. Cell supernatants were collected and frozen at −80°C until assayed.

    Product #171E – Anthrax Protective Antigen (PA), Recombinant from B. anthracis
    Prodcut #172 – Anthrax Lethal Factor (LF), Recombinant from B. anthracis

HERC5-catalyzed ISGylation potentiates cGAS-mediated innate immunity

Chu, L;Qian, L;Chen, Y;Duan, S;Ding, M;Sun, W;Meng, W;Zhu, J;Wang, Q;Hao, H;Wang, C;Cui, S;

Product: Pertussis Toxin from B. pertussis, Lyophilized (Salt-Free)

The astrocyte-produced growth factor HB-EGF limits autoimmune CNS pathology

Linnerbauer, M;Lößlein, L;Vandrey, O;Peter, A;Han, Y;Tsaktanis, T;Wogram, E;Needhamsen, M;Kular, L;Nagel, L;Zissler, J;Andert, M;Meszaros, L;Hanspach, J;Zuber, F;Naumann, UJ;Diebold, M;Wheeler, MA;Beyer, T;Nirschl, L;Cirac, A;Laun, FB;Günther, C;Winkler, J;Bäuerle, T;Jagodic, M;Hemmer, B;Prinz, M;Quintana, FJ;Rothhammer, V;

Product: Pertussis Toxin from B. pertussis, Lyophilized in Buffer

  • EAE

    EAE was induced as previously described52. In brief, 8–12-week-old female C57Bl/6J mice were immunized using 150 μg of MOG35–55 (Genemed Synthesis, 110582) mixed with freshly prepared Complete Freund’s Adjuvant (using 20 ml of Incomplete Freund’s Adjuvant (BD Biosciences, no. BD263910) mixed with 100 mg of Myobacterium tuberculosis H37Ra (BD Biosciences, no. 231141)) at a ratio of 1:1 (v/v at a concentration of 5 mg ml−1). All mice received two subcutaneous injections of 100 μl each of the MOG35-55/CFA mix. All mice then received a single intraperitoneal injection of 200 ng of pertussis toxin (List Biological Laboratories, no. 180) at a concentration in 200 μl of PBS. …

    Product #180 – Pertussis Toxin from B. pertussis, Lyophilized in Buffer

Product: Tetanus Toxin from Clostridium tetani

  • Tetanus toxin labeling

    Alexa Fluor®647 was attached to the tetanus toxin (List Biologicals cat. no. 19050A2) according to the manufacturer’s protocol from Alexa Fluor®647 Labeling Kit (Microscale Protein Labeling Kit, cat. no. A30009; ThermoFisher Scientific) and stored at −20°C. Quantification of the Alexa Fluor® 647 ratio per tetanus toxin was obtained by scanning measurements using the NanoDrop One c device (Thermo Fisher Scientific) with 280 and 650 nm readings. The average dye per mole of protein obtained was 1.7 moles.

    Tetanus toxin internalization inhibition assay

    The TeNT entry inhibition by mAbs was initiated by the pre-incubation of 25 nM TeNT-Alexa-Fluor 647 and 25 nM or 50 nM mAbs in Neurobasal-A medium on an orbital shaker at 37°C, 5% CO2 for 1 hour. The mixtures and increased concentrations of TeNT-Alexa-Fluor 647 (25 nM, 50 nM, and 100 nM) were added to cells for 1 hour at 37°C and 5% CO2. Cells were washed twice in 2% formaldehyde solution in PBS and processed for immunofluorescence.

    Product #190 – Tetanus Toxin from Clostridium tetani